CN105246510A - 细胞培养培养基和抗体生产方法 - Google Patents

细胞培养培养基和抗体生产方法 Download PDF

Info

Publication number
CN105246510A
CN105246510A CN201480027392.9A CN201480027392A CN105246510A CN 105246510 A CN105246510 A CN 105246510A CN 201480027392 A CN201480027392 A CN 201480027392A CN 105246510 A CN105246510 A CN 105246510A
Authority
CN
China
Prior art keywords
cell culture
culture medium
insulin
concentration
hydrolyzate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480027392.9A
Other languages
English (en)
Chinese (zh)
Inventor
V·卡瓦利亚尔
N·维贾雅桑卡兰
L·布朗
T·迪罗科
N·麦克奈特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51537877&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105246510(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN105246510A publication Critical patent/CN105246510A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201480027392.9A 2013-03-15 2014-03-14 细胞培养培养基和抗体生产方法 Pending CN105246510A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361801247P 2013-03-15 2013-03-15
US61/801,247 2013-03-15
PCT/US2014/029758 WO2014145091A1 (en) 2013-03-15 2014-03-14 Cell culture media and methods of antibody production

Publications (1)

Publication Number Publication Date
CN105246510A true CN105246510A (zh) 2016-01-13

Family

ID=51537877

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480027392.9A Pending CN105246510A (zh) 2013-03-15 2014-03-14 细胞培养培养基和抗体生产方法

Country Status (12)

Country Link
US (5) US9441035B2 (enExample)
EP (1) EP2968544A4 (enExample)
JP (2) JP2016513478A (enExample)
KR (1) KR102202476B1 (enExample)
CN (1) CN105246510A (enExample)
AR (1) AR095348A1 (enExample)
BR (1) BR112015022529A2 (enExample)
CA (1) CA2903589A1 (enExample)
HK (1) HK1213179A1 (enExample)
MX (1) MX366112B (enExample)
RU (1) RU2015144020A (enExample)
WO (1) WO2014145091A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109890416A (zh) * 2016-11-07 2019-06-14 西雅图基因公司 工程化半胱氨酸帽的分布
CN111500662A (zh) * 2018-06-25 2020-08-07 深圳市菲鹏生物制药股份有限公司 调节cho-k1表达系统所分泌抗体的酸性峰含量的方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2464725T2 (sl) 2009-08-11 2025-06-30 F. Hoffmann-La Roche Ag Proizvodnja beljakovin v medijih za celične kulture brez glutamina
KR102007930B1 (ko) 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
AR104050A1 (es) 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados
GB201708655D0 (en) * 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
SG11202004380QA (en) 2017-12-22 2020-06-29 Regeneron Pharma System and method for characterizing drug product impurities
CA3201327A1 (en) * 2020-12-08 2022-06-16 Partner Therapeutics, Inc. Manufacture of granulocyte macrophage-colony stimulating factor
JP2023554489A (ja) * 2020-12-22 2023-12-27 ノバルティス アーゲー 細胞培養中の分泌された組換え発現タンパク質中のシステイン残基の酸化レベルを低減するための方法
US12448456B2 (en) * 2021-05-03 2025-10-21 Boehringer Ingelheim International Gmbh Method for producing spesolimab
EP4493710A1 (en) * 2022-04-06 2025-01-22 Kashiv Biosciences, LLC An improved cell culture process for production of protein
WO2024099551A1 (en) * 2022-11-09 2024-05-16 Infors Ag Incubator avoiding condensation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1778902A (zh) * 2005-09-29 2006-05-31 华东理工大学 适用于多种动物细胞大规模培养的无血清培养基
CN101603026A (zh) * 2009-06-19 2009-12-16 华东理工大学 适于动物细胞产品生产的无动物来源低蛋白培养基
US20110129926A1 (en) * 1997-02-14 2011-06-02 Life Technologies Corporation Dry powder cell culture products and methods of production thereof
CN102471377A (zh) * 2009-07-24 2012-05-23 霍夫曼-拉罗奇有限公司 优化抗体的生产
WO2012145682A1 (en) * 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
CN102812121A (zh) * 2010-01-25 2012-12-05 文特里亚生物科学公司 用于改善蛋白质生产的方法和组合物

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
JP3951062B2 (ja) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
AU729039C (en) 1996-08-30 2001-08-02 Upfront Chromatography A/S Isolation of immunoglobulins
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
US20080318254A9 (en) 1997-03-10 2008-12-25 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ATE531812T1 (de) 1997-12-05 2011-11-15 Scripps Research Inst Humanisierung von nager-antikörpern
US6528286B1 (en) * 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
DE60039596D1 (de) 1999-03-30 2008-09-04 Japan Tobacco Inc Verfahren zur herstellung von monoklonalen antikörpern
EP1222292B1 (en) 1999-10-04 2005-08-31 Medicago Inc. Method for regulating transcription of foreign genes in the presence of nitrogen
ATE464062T1 (de) 1999-10-04 2010-04-15 Novartis Vaccines & Diagnostic Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP2005519580A (ja) 2001-05-16 2005-07-07 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ 非ヒト動物由来のヒト抗肺炎球菌抗体
AU2002356749A1 (en) * 2001-11-28 2003-06-10 Hermann Katinger Process for the production of polypeptides in mammalian cell cultures
CA2492143A1 (en) 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
JP2007525410A (ja) 2003-01-17 2007-09-06 ザ リサーチ ファンデーション オブ ステイト ユニバーシティ オブ ニューヨーク 膵臓癌に関連する抗原、それらに対する抗体、及び診断方法及び処置方法
CA2526398C (en) 2003-05-21 2014-07-15 Medarex, Inc. Human monoclonal antibodies against bacillus anthracis protective antigen
WO2006047380A2 (en) * 2004-10-22 2006-05-04 Amgen, Inc. Method and media for single cell serum-fee culture of cho cells
JP5523674B2 (ja) * 2005-02-11 2014-06-18 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 植物タンパク質加水分解産物を含有する血清フリーの細胞培養液におけるポリペプチドの生産
CN101802192A (zh) * 2007-10-15 2010-08-11 中外制药株式会社 抗体的制备方法
CN103599541A (zh) 2008-09-10 2014-02-26 弗·哈夫曼-拉罗切有限公司 用于防止蛋白质氧化降解的组合物和方法
CN103952376A (zh) * 2008-09-24 2014-07-30 米迪缪尼有限公司 培养细胞、增殖和纯化病毒的方法
EP2351833B1 (en) * 2008-10-28 2018-07-18 Chugai Seiyaku Kabushiki Kaisha Peptide-containing culture medium for culturing animal cell
SI2464725T2 (sl) * 2009-08-11 2025-06-30 F. Hoffmann-La Roche Ag Proizvodnja beljakovin v medijih za celične kulture brez glutamina
US20130281355A1 (en) * 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US8956830B2 (en) * 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110129926A1 (en) * 1997-02-14 2011-06-02 Life Technologies Corporation Dry powder cell culture products and methods of production thereof
CN1778902A (zh) * 2005-09-29 2006-05-31 华东理工大学 适用于多种动物细胞大规模培养的无血清培养基
CN101603026A (zh) * 2009-06-19 2009-12-16 华东理工大学 适于动物细胞产品生产的无动物来源低蛋白培养基
CN102471377A (zh) * 2009-07-24 2012-05-23 霍夫曼-拉罗奇有限公司 优化抗体的生产
CN102812121A (zh) * 2010-01-25 2012-12-05 文特里亚生物科学公司 用于改善蛋白质生产的方法和组合物
WO2012145682A1 (en) * 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109890416A (zh) * 2016-11-07 2019-06-14 西雅图基因公司 工程化半胱氨酸帽的分布
CN109890416B (zh) * 2016-11-07 2024-04-30 西雅图基因公司 工程化半胱氨酸帽的分布
CN111500662A (zh) * 2018-06-25 2020-08-07 深圳市菲鹏生物制药股份有限公司 调节cho-k1表达系统所分泌抗体的酸性峰含量的方法

Also Published As

Publication number Publication date
US20200347122A1 (en) 2020-11-05
HK1213179A1 (zh) 2016-06-30
EP2968544A1 (en) 2016-01-20
JP2019193643A (ja) 2019-11-07
BR112015022529A2 (pt) 2017-07-18
JP2016513478A (ja) 2016-05-16
US20200291103A1 (en) 2020-09-17
US20170051049A1 (en) 2017-02-23
MX2015011781A (es) 2016-04-04
KR102202476B1 (ko) 2021-01-12
EP2968544A4 (en) 2016-10-12
MX366112B (es) 2019-06-26
US9441035B2 (en) 2016-09-13
US20140308273A1 (en) 2014-10-16
WO2014145091A1 (en) 2014-09-18
RU2015144020A (ru) 2017-04-21
KR20150131258A (ko) 2015-11-24
US20160102141A1 (en) 2016-04-14
AR095348A1 (es) 2015-10-07
CA2903589A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
CN105246510A (zh) 细胞培养培养基和抗体生产方法
CN111440758B (zh) 用于多肽生产的细胞培养组合物和方法
JP7788307B2 (ja) 組換えタンパク質のグリコシル化を調節するためのｎ－グリコシル化経路制御因子の過剰発現
US20140199728A1 (en) Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
TW200831669A (en) Cell culture improvements
US11299760B2 (en) Use of monensin to regulate glycosylation of recombinant proteins
EP3492582A1 (en) Cell culture methods
JP2017516484A (ja) タンパク質生産のための細胞培養工程
EP3630946A1 (en) Cell culture methods
MX2011006549A (es) Suplemento alimenticio para el cultivo de celula de mamifero y metodos de uso.
US20240425894A1 (en) Cell culture processes
KR20150131280A (ko) 세포 배양액에서 암모니아 생성을 제어하기 위한 트리카르복실산（ｔｃａ）중간체의 용도
HK40002355A (en) Methods of decreasing trisulfide bonds during recombinant production of polypeptides
HK40032375A (en) Cell culture compositions and methods for polypeptide production

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1213179

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160113

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1213179

Country of ref document: HK